1. Scrip
  2. >>Business
  3. >>Earnings

Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens

 
• By Alaric DeArment

Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.

• Source: Shutterstock

Gilead Sciences, Inc. showed a strengthening of its core business in the second quarter of 2023 as sales climbed higher even when factoring in the COVID-19 antiviral drug Veklury (remdesivir), which had carried Gilead’s sales during the pandemic and whose declines had in multiple quarters caused the company’s revenues to fall, remain flat or rise only slightly on a year-over-year basis.

The Foster City, CA-based company released its second quarter sales on 3 August, reporting revenue of $6.6bn, up from $6.3bn in the second quarter of 2022. Excluding Veklury, that marked 11% year-over-year growth. But even when including Veklury, that still constituted a 5% increase compared with a year ago

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.